Altria Group (US:MO), a leading tobacco company active in the cannabis industry, said Monday that it abandoned its warrant to buy more Cronos Group (CA:CRON, US:CRON) shares and would see a $483 million loss on its 2022 U.S. federal consolidated income ...

Cronos remains a Strong Buy, supported by robust fundamentals, international expansion, and a depressed $1B valuation with $784M in cash. Learn more about CRON stock here.

Altria Group, Inc. (NYSE: MO) today reports our 2025 third-quarter and nine-months business results, announces the expansion of our existing share repurchase program and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS).

We reaffirm our guidance to deliver 2026 full-year adjusted diluted earnings per share (EPS) in a range of $5.56 to $5.72, representing a growth rate of 2.5% to 5.5% from a base of $5.42 in 2025. We expect 2026 adjusted diluted EPS growth to be weighted to the second half of the year,

Cronos Group operates in a highly competitive industry but has a marked advantage over its peers owing to its vastly superior balance sheet. This superiority is a result of a 2019 investment by Altria of $1.8 billion. CRON has experienced consistent cash ...